BCAL Diagnostics (ASX:BDX) DeferredTaxAndRevenue: A$0.00 Mil (As of Dec. 2025)


What is BCAL Diagnostics DeferredTaxAndRevenue?

BCAL Diagnostics ASX:BDX +1.39% DeferredTaxAndRevenue is A$0.00 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

BCAL Diagnostics's current deferred tax and revenue for the quarter that ended in Dec. 2025 was A$0.00 Mil.

BCAL Diagnostics DeferredTaxAndRevenue Related Terms

BCAL Diagnostics DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for BCAL Diagnostics's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BCAL Diagnostics DeferredTaxAndRevenue Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
DeferredTaxAndRevenue
0.00 0.00 0.00 0.00

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of A$0.00 Mil mean?
BCAL Diagnostics (ASX:BDX) has a DeferredTaxAndRevenue of A$0.00 Mil as of Dec. 2025. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on BCAL Diagnostics.
Is BCAL Diagnostics' DeferredTaxAndRevenue too high?
BCAL Diagnostics' current DeferredTaxAndRevenue is A$0.00 Mil.
How does BCAL Diagnostics' DeferredTaxAndRevenue compare to TMO and DHR?
BCAL Diagnostics' DeferredTaxAndRevenue of A$0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Medical Diagnostics & Research company?
A good DeferredTaxAndRevenue depends on the Medical Diagnostics & Research industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on BCAL Diagnostics. BCAL Diagnostics's current DeferredTaxAndRevenue is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current DeferredTaxAndRevenue of A$0.00 Mil. The current DeferredTaxAndRevenue is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current DeferredTaxAndRevenue is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BCAL Diagnostics Business Description

Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.